Post Exubera#174;: Can New Life be Breathed Back into Inhaled Insulin?
By Business Review Editor
Pharma Deals Review: Vol 2008 Issue 92 (Table of Contents)
Published: 1 Feb-2008
DOI: 10.3833/pdr.v2008.i92.221 ISSN: 1756-7874
Section: Features
Fulltext:
Abstract
One of the biggest drug delivery stories of 2007 has been the flop of Pfizer#8217;s Exubera#174;, the inhaled insulin product aimed at a multibillion dollar market...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS